<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303793</url>
  </required_header>
  <id_info>
    <org_study_id>congenital heart disease</org_study_id>
    <nct_id>NCT04303793</nct_id>
  </id_info>
  <brief_title>Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.</brief_title>
  <official_title>Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare safety, efficacy and procedural outcome of percutaneous PDA closure using
      different approaches for better characterization of device selection criteria.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural safety</measure>
    <time_frame>one month</time_frame>
    <description>studying the occurrence of catheter related complications including
Occurrence of vascular access hematoma(Yes/No )
Occurrence of contrast induced nephropathy (Yes/No)
PDA closure Device embolization (Yes/No)
Cardiac tamponade (Yes/No)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural efficacy</measure>
    <time_frame>one month</time_frame>
    <description>timing of complete closure of the PDA with no residual shunts
Residual left to right shunt (Yes/No)
Degree of the residual shunt (Trace, Mild , Moderate, severe)
Timing of closure of the shunt( immediately postprocedural, 24 hours post procedural , 1 month post procedural )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural outcomes</measure>
    <time_frame>one month</time_frame>
    <description>comparison of echocardiography data that will be done pre catheter closure, one day post procedure and one month later ( left ventricular and atrial dimensions-left ventricular ejection fraction-pulmonary artery systolic pressure- degree of tricuspid regurge)</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Congenital Heart Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous PDA closure</intervention_name>
    <description>transcatheter patent ductus arteriosus closure</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients who are candidate for transcatheter PDA closure

        Exclusion Criteria:

          1. Patients with PDA dependent pulmonary circulation.

          2. Patients with small sized PDA which is silent by auscultation

          3. Patients with large sized PDA which is unsuitable for Trans-catheter closure

          4. Patients with PDA and severe irreversible pulmonary hypertension (Eisenmenger's
             syndrome) (7).

          5. Patients with active infection or active infective endarteritis.

          6. Patients refusing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Mohamed Moheb El-Din</last_name>
    <phone>01060964666</phone>
    <email>ahmedmoheb34567@gmail.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Moheb El-Din</investigator_full_name>
    <investigator_title>Assistant lecturer of cardiovascular medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

